Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 9/20 | 0.59 |
| ▸ | AKR1C2 | P52895 | 9/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6931615 | 0.88 | HTT (0.63) | AKR1C3AKR1C2HTTALDH1A1HPGD | |
| SCHEMBL1607798 | 0.87 | AKR1C3 (0.64) | AKR1C3AKR1C2HTTALDH1A1HPGD | |
| SCHEMBL1607722 | 0.84 | AKR1C3 (0.57) | AKR1C3AKR1C2HTTALDH1A1HPGD | |
| SCHEMBL19061608 | 0.83 | AKR1C3 (0.56) | AKR1C3AKR1C2HTTALDH1A1HPGD | |
| SCHEMBL18375151 | 0.82 | AKR1C3 (0.64) | AKR1C3AKR1C2HTTKDM4ERAB9A | |
| SCHEMBL18087540 | 0.81 | AKR1C3 (0.63) | AKR1C3AKR1C2HTTALDH1A1RAB9A | |
| SCHEMBL16710354 | 0.80 | AKR1C3 (0.59) | AKR1C3AKR1C2HTTALOX5ABCB1 | |
| SCHEMBL20472134 | 0.79 | AKR1C3 (0.61) | AKR1C3AKR1C2HTTALOX5ABCB1 | |
| SCHEMBL17049938 | 0.79 | HTT (0.58) | AKR1C3AKR1C2HTTALDH1A1HPGD | |
| SCHEMBL20660497 | 0.78 | HTT (0.53) | AKR1C3AKR1C2HTTALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4585267-A2 | COUMARIN BASED HSP90 INHIBITORS WITH UREA AND ETHER SUBSTITUENTS | The University of Kansas (US) | 2025-07-16 | — | — | EP | disclosed |
| EP-3068778-B1 | COUMARIN BASED HSP90 INHIBITORS WITH UREA AND ETHER SUBSTITUENTS | UNIV KANSAS (US) | 2025-02-19 | — | — | EP | disclosed |
| EP-3066072-B1 | BIPHENYLAMIDE DERIVATIVE HSP90 INHIBITORS | UNIV KANSAS (US) | 2021-11-03 | — | — | EP | disclosed |
| EP-3066072-B1 | BIPHENYLAMIDE DERIVATIVE HSP90 INHIBITORS | UNIV KANSAS (US) | 2021-11-03 | — | — | EP | disclosed |
| US-10745386-B2 | Coumarin based HSP90 inhibitors with urea and ether substituents | UNIVERSITY OF KANSAS (US) | 2020-08-18 | — | — | US | disclosed |
| US-10745386-B2 | Coumarin based HSP90 inhibitors with urea and ether substituents | UNIVERSITY OF KANSAS (US) | 2020-08-18 | — | — | US | disclosed |
| US-10689344-B2 | Biphenylamide derivative Hsp90 inhibitors | UNIVERSITY OF KANSAS (US) | 2020-06-23 | — | — | US | disclosed |
| US-10689344-B2 | Biphenylamide derivative Hsp90 inhibitors | UNIVERSITY OF KANSAS (US) | 2020-06-23 | — | — | US | disclosed |
| US-20190023698-A1 | COUMARIN BASED HSP90 INHIBITORS WITH UREA AND ETHER SUBSTITUENTS | UNIVERSITY OF KANSAS (US) | 2019-01-24 | — | — | US | disclosed |
| US-20190023698-A1 | COUMARIN BASED HSP90 INHIBITORS WITH UREA AND ETHER SUBSTITUENTS | UNIVERSITY OF KANSAS (US) | 2019-01-24 | — | — | US | disclosed |
| US-20160272584-A1 | BIPHENYLAMIDE DERIVATIVE HSP90 INHIBITORS | UNIVERSITY OF KANSAS (US) | 2016-09-22 | — | — | US | disclosed |
| EP-3066072-A1 | BIPHENYLAMIDE DERIVATIVE HSP90 INHIBITORS | The University of Kansas (US) | 2016-09-14 | — | — | EP | disclosed |
| US-9120774-B2 | Novobiocin analogues having modified sugar moieties | UNIVERSITY OF KANSAS (US) | 2015-09-01 | — | — | US | disclosed |
| WO-2015070091-A1 | BIPHENYLAMIDE DERIVATIVE HSP90 INHIBITORS | THE UNIVERSITY OF KANSAS (US) | 2015-05-14 | — | — | WO | disclosed |
| WO-2015070091-A1 | BIPHENYLAMIDE DERIVATIVE HSP90 INHIBITORS | THE UNIVERSITY OF KANSAS (US) | 2015-05-14 | — | — | WO | disclosed |
| US-8692018-B2 | Application of iridium complexes in asymmetric catalytic hydrogenation of unsaturated carboxylic acids | Zheijiang Jiuzhou Pharmaceutical Co., Ltd. (CN) | 2014-04-08 | — | — | US | disclosed |
| US-20120252745-A1 | NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-10-04 | — | — | US | disclosed |
| US-20110082098-A1 | NOVOBIOCIN ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE | UNIVERSITY OF KANSAS (US) | 2011-04-07 | — | — | US | disclosed |
| WO-2011041593-A1 | NOVOBIOCIN ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE | UNIVERSITY OF KANSAS (US) | 2011-04-07 | — | — | WO | disclosed |
| WO-2010096650-A1 | NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES | UNIVERSITY OF KANSAS (US) | 2010-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10745386-B2 | Coumarin based HSP90 inhibitors with urea and ether substituents | HSP90B1, HSP90AA1, HSP90AB1 | AKR1C3 1194/4885AKR1C2 1431/4885HTT 497/4885 |
| US-10689344-B2 | Biphenylamide derivative Hsp90 inhibitors | HSP90AB1, HSP90AA1, HSP90AB2P | AKR1C3 1964/4885AKR1C2 2289/4885HTT 285/4885 |
| US-20120252745-A1 | NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES | HSP90AB1, HSP90AB2P, HSP90B1 | AKR1C3 2899/4885AKR1C2 2362/4885HTT 3727/4885 |
| US-20160272584-A1 | BIPHENYLAMIDE DERIVATIVE HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90AB2P | AKR1C3 1964/4885AKR1C2 2289/4885HTT 285/4885 |
| US-20190023698-A1 | COUMARIN BASED HSP90 INHIBITORS WITH UREA AND ETHER SUBSTITUENTS | HSP90B1, HSP90AA1, HSP90AB1 | AKR1C3 1122/4885AKR1C2 1336/4885HTT 530/4885 |
| US-20110082098-A1 | NOVOBIOCIN ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE | PKD1, PKD2, HSP90B1 | AKR1C3 3110/4885AKR1C2 2777/4885HTT 1080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.